https://ethz.ch/en/industry/entrepreneurship.html  

8952 Schlieren, Wagistrasse 18

 entrepreneurship@ethz.ch

Excellence in entrepreneurship at ETH Zurich is driven by world-​class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions. 

https://www.wysszurich.ch/projects/somagenetix  

8952 Schlieren, Wagistrasse 23

Gene therapy solutions for patients with severe inherited diseases.

https://www.campus-schlieren.uzh.ch/en.html  

8952 Schlieren, Wagistrasse 12

The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.

https://www.repertoire.com/  

8952 Schlieren, Wagistrasse 27

 info@repertoire.com

The key to our strategy lies in understanding the inner workings of the immune synapse – the interaction between the T cell and the antigen presenting cell which dictates the immune code that tells a T cell to become toxic and to kill the infected tissue. Our scientists created and developed the DECODETM and DEPLOY suite of technologies, which allows in-depth characterization of TCR-antigen pairings – and the ability to rationally design and clinically develop targeted immune medicines. Our scientists also have developed novel technologies that attach potent immunomodulators to T cells, enabling us to deliver potent cytokines such as IL-15 or IL-12 directly to tumors by using the natural homing power of the T cells to traffic to diseased tissue.